As such, they completed a disclosure of interest form, which was reviewed by ASH and is available as supplements 2 and 3. ORCID profiles: A.A., 0000-0002-0931-7851; Y.Z., 0000- 0002-4174-0641. Correspondence: Daniel M. Witt, Department of Pharmaco- therapy, College of Pharmacy, University of Utah, 30 South 2000 East, 4323, Salt Lake City, UT 84112; e-mail: dan.witt@pharm. utah.edu. References 1. Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism [published correction appears in J Thromb Thrombolysis. 2016;42(2):296-311]. J Thromb Thrombolysis. 2016;41(1):15-31. 2. Schu nemann HJ, Wiercioch W, Etxeandia I, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2014;186(3):E123-E142. 3. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Washington, DC: National Academies Press; 2011. 4. Qaseem A, Forland F, Macbeth F, Ollenschla ger G, Phillips S, van der Wees P; Board of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7): 525-531. 5. Schu nemann HJ, Al-Ansary LA, Forland F, et al; Board of Trustees of the Guidelines International Network. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med. 2015;163(7):548-553. 6. Alonso-Coello P, Oxman AD, Moberg J, et al; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089. 7. Alonso-Coello P, Schu nemann HJ, Moberg J, et al; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016. 8. Atkins D, Eccles M, Flottorp S, et al; GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations. I: Critical appraisal of existing approaches. BMC Health Serv Res. 2004;4(1):38. 9. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394. 10. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. 11. Schu nemann HJ, Best D, Vist G, Oxman AD; GRADE Working Group. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677-680. 12. Schu nemann HJ, Mustafa R, Brozek J, et al; GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89-98. 13. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published corrections appear in Chest. 2012;141(5):1369 and Chest. 2013; 144(2):721]. Chest. 2012;141(suppl 2):e24S-e43S. 14. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e278S- e325S. 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3283 15. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest. 2012;141(5):1369]. Chest. 2012;141(suppl 2):e227S-e277S. 16. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e195S-e226S. 17. Lo B, Fields M. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academic Press, Institute of Medicine; 2009. 18. Akl EA, El-Hachem P, Abou-Haidar H, Neumann I, Schu nemann HJ, Guyatt GH. Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study. J Clin Epidemiol. 2014;67(11):1222-1228. 19. Guyatt G, Akl EA, Hirsh J, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11): 738-741. 20. Schu nemann HJ, Osborne M, Moss J, et al; ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med. 2009;180(6):564-580. 21. Broz ek J, Nowak A, Kunstman P, Schu nemann HJ. GRADEpro Guideline Development Tool (G2DT). Available at: www.guidelinedevelopment.org. Accessed 17 July 2018. 22. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4): 395-400. 23. Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost. 2005;3(1):100-102. 24. Cosmi B, Filippini M, Tonti D, et al; STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost. 2012;10(6):1026-1035. 25. Di Nisio M, Vedovati MC, Riera-Mestre A, et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. Thromb Haemost. 2016;116(4):739-746. 26. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146(1):33-41. 27. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42-48. 28. Washam JB, Hellkamp AS, Lokhnygina Y, et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF Trial). Am J Cardiol. 2017;120(4):588-594. 29. Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016; (7):CD003839. 30. Azarnoush K, Camilleri L, Aublet-Cuvelier B, et al. Results of the first randomized French study evaluating self-testing of the international normalized ratio. J Heart Valve Dis. 2011;20(5):518-525. 31. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med. 2000;133(9):687-695. 32. Christensen H, Lauterlein JJ, S rensen PD, Petersen ER, Madsen JS, Brandslund I. Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment. Telemed J E Health. 2011;17(3):169-176. 33. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in The Netherlands: a randomized clinical trial. Arch Intern Med. 2003;163(21):2639-2646. 34. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis. 1998;5 suppl 1(3):19-24. 35. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126(4):557-564. 36. Matchar DB, Jacobson A, Dolor R, et al; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608-1620. 37. Rasmussen RS, Corell P, Madsen P, Overgaard K. Effects of computer-assisted oral anticoagulant therapy. Thromb J. 2012;10(1):17. 38. Ryan F, Byrne S, O Shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost. 2009;7(8):1284-1290. 39. Thompson JL, Burkhart HM, Daly RC, et al. Anticoagulation early after mechanical valve replacement: improved management with patient self-testing. J Thorac Cardiovasc Surg. 2013;146(3):599-604. 40. White RH, McCurdy SA, von Marensdorff H, Woodruff DE Jr, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med. 1989;111(9):730-737. 41. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost. 2004;2(4):584-591. 42. Matchar DB, Love SR, Jacobson AK, et al. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. 2015;40(1):17-25. 43. Sharma P, Scotland G, Cruickshank M, et al. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/ INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. Health Technol Assess. 2015;19(48):1-172. 44. Phibbs CS, Love SR, Jacobson AK, et al; writing for the THINRS Executive Committee and Site Investigators. At-home versus in-clinic INR monitoring: a cost-utility analysis from the Home INR Study (THINRS). J Gen Intern Med. 2016;31(9):1061-1067. 45. Stevanovic J, Postma MJ, Le HH. Budget impact of increasing market share of patient self-testing and patient self-management in anticoagulation. Value Health. 2016;19(4):383-390. 46. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11(38):iii-iv, ix-66. 47. Guidance on the Use of Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy. CADTH Optimal Use Reports. Ottawa, ON, Canada: Canadian Agency for Drugs and Technologies in Health; 2014. 48. Dignan R, Keech AC, Gebski VJ, Mann KP, Hughes CF; Warfarin SMART Investigators. Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. Int J Cardiol. 2013;168(6):5378-5384. 49. Soliman Hamad MA, van Eekelen E, van Agt T, van Straten AH. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur J Cardiothorac Surg. 2009;35(2):265-269. 50. Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol. 2002;55(11):845-849. 51. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial. Thromb Haemost. 2007;97(3):408-416. 52. Verret L, Couturier J, Rozon A, et al. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. Pharmacotherapy. 2012;32(10):871-879. 53. Fitzmaurice DA, Murray ET, McCahon D, et al. Self management of oral anticoagulation: randomised trial. BMJ. 2005;331(7524):1057. 54. Sunderji R, Campbell L, Shalansky K, Fung A, Carter C, Gin K. Outpatient self-management of warfarin therapy: a pilot study. Pharmacotherapy. 1999; 19(6):787-793. 55. Grunau BE, Wiens MO, Harder KK. Patient self-management of warfarin therapy: pragmatic feasibility study in Canadian primary care. Can Fam Physician. 2011;57(8):e292-e298. 56. Mene ndez-Ja ndula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med. 2005;142(1):1-10. 57. Vo ller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). Z Kardiol. 2005;94(3):182-186. 58. Ko rtke H, Ko rfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg. 2001;72(1):44-48. 59. Sawicki PT; Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA. 1999;281(2):145-150. 60. Christensen TD, Maegaard M, S rensen HT, Hjortdal VE, Hasenkam JM. Self-management versus conventional management of oral anticoagulant therapy: A randomized, controlled trial. Eur J Intern Med. 2006;17(4):260-266. 61. Sidhu P, O Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg. 2001;72(5):1523-1527. 62. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 2000;356(9224):97-102. 63. Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation. 2003;108(suppl 1):II75-II78. 64. Koertke H, Zittermann A, Minami K, et al. Low-dose international normalized ratio self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement. Ann Thorac Surg. 2005;79(6):1909-1914; discussion 14. 65. Koertke H, Zittermann A, Tenderich G, et al. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J. 2007;28(20):2479-2484. 66. Koertke H, Zittermann A, Wagner O, et al. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. Ann Thorac Surg. 2010;90(5):1487-1493. 67. Koertke H, Zittermann A, Wagner O, Koerfer R. Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg. 2007;83(1):24-29. 68. Ko rtke H, Minami K, Breymann T, et al. INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial) [in German]. Z Kardiol. 2001;90(suppl 6):118-124. 69. McCahon D, Fitzmaurice DA, Murray ET, et al. SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]. BMC Fam Pract. 2003;4:11. 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3285 70. McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA. Does self-management of oral anticoagulation therapy improve quality of life and anxiety? Fam Pract. 2011;28(2):134-140. 71. Murray E, Fitzmaurice D, McCahon D, Fuller C, Sandhur H. Training for patients in a randomised controlled trial of self management of warfarin treatment. BMJ. 2004;328(7437):437-438. 72. Siebenhofer A, Hemkens LG, Rakovac I, Spat S, Didjurgeit U; SPOG 601 Study Group. Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life. Thromb Res. 2012;130(3):e60-e66. 73. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U; SPOG 601 Study Group. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost. 2008;100(6):1089-1098. 74. Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006;174(13):1847-1852. 75. Jowett S, Bryan S, Murray E, et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol. 2006; 134(6):632-639. 76. Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011;4(3):276-282. 77. Schaefer C, Wuillemin WA, Kessels A, Jacobson A, Nagler M. Predictors of anticoagulation quality in 15 834 patients performing patient self- management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated Patients. Br J Haematol. 2016;175(4):677-685. 78. Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) Clinical Quality Study Group. Center-related determinants of VKA anticoagulation quality: a prospective, multicenter evaluation. PLoS One. 2015;10(12):e0144314. 79. Pengo V, Barbero F, Biasiolo A, Pegoraro C, Cucchini U, Iliceto S. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol. 2003;120(6):944-947. 80. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011;155(10):653-659. 81. Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014; 129(13):1407-1414. 82. Lidstone V, Janes S, Stross P. INR: intervals of measurement can safely extend to 14 weeks. Clin Lab Haematol. 2000;22(5):291-293. 83. Shalev V, Rogowski O, Shimron O, et al. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res. 2007;120(2):201-206. 84. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-684. 85. Leizorovicz A, Siguret V, Mottier D, et al; Innohep in Renal Insufficiency Study Steering Committee. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep in Renal Insufficiency Study (IRIS). Thromb Res. 2011;128(1):27-34. 86. Bazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41-50. 87. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43(6):586-590. 88. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J. 2004;148(4): 582-589. 89. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. 2002;25(10):725-733. 90. Peng YG, Eikelboom JW, Tenni P, McQuillan A, Thorne J. Renal function, peak anti Xa levels and enoxaparin dosing. J Pharm Pract Res. 2004; 34(1):14-17. 91. Siguret V, Pautas E, Fe vrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84(5):800-804. 92. Sule AA, Tay JC, Arul E. Effect of enoxaparin on peak and trough levels of antifactor Xa in patients with a creatinine clearance of less than 30 mL/min. Int J Angiol. 2009;18(4):184-186. 93. Ballew A, Lee Y, Vega J, Duong HN. Evaluating current recommended dose of enoxaparin in renally impaired and morbidly obese patients by monitoring anti-factor Xa levels [abstract]. Pharmacotherapy. 2014;34(10):e273-e274. 94. Lachish T, Rudensky B, Slotki I, Zevin S. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Pharmacotherapy. 2007;27(10):1347-1352. 95. Yildirim T, Kocak T, Buyukasik Y, et al. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5? Blood Coagul Fibrinolysis. 2012;23(8):700-704. 96. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125(3):856-863. 97. Barras M. Anti-Xa assays. Aust Prescr. 2013;36(3):98-101. 98. Favaloro EJ, Bonar R, Aboud M, et al; RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol. 2005;11(3):157-162. 99. Favaloro EJ, Bonar R, Sioufi J, et al; Royal College Pathologists of Australasia Quality Assurance Program in Haematology. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology. 2005;37(3):234-238. 100. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology. 2011;43(7):682-692. 101. Egan G, Ensom MH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm. 2015; 68(1):33-47. 102. Deal EN, Hollands JM, Riney JN, Skrupky LP, Smith JR, Reichley RM. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis. 2011;32(2):188-194. 103. Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2015;39(4):516-521. 104. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87(5):817-823. 105. Smith J, Canton EM. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm. 2003;60(7):683-687. 106. Beyer-Westendorf J, Fo rster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-962. 107. Beynon C, Sakowitz OW, Sto rzinger D, et al. Intracranial haemorrhage in patients treated with direct oral anticoagulants. Thromb Res. 2015;136(3): 560-565. 108. Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Bu ller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost. 2015;13(9):1590-1596. 109. Kumar R, Smith RE, Henry BL. A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage: a single-center university hospital experience. J Intensive Care Med. 2015;30(8):462-472. 110. Pahs L, Beavers C, Schuler P. The real-world treatment of hemorrhages associated with dabigatran and rivaroxaban: a multicenter evaluation. Crit Pathw Cardiol. 2015;14(2):53-61. 111. Piccini JP, Garg J, Patel MR, et al; ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35(28):1873-1880. 112. Purrucker JC, Haas K, Rizos T, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73(2):169-177. 113. Senger S, Keiner D, Hendrix P, Oertel J. New target-specific oral anticoagulants and intracranial bleeding: management and outcome in a single-center case series. World Neurosurg. 2016;88:132-139. 114. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial [published correction appears in Am Heart J. 2015;169(4): 594]. Am Heart J. 2015;169(1):25-30. 115. Mahaffey KW, Hellkamp AS, Patel MR, et al. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes. 2013;6(4):470-478. 116. Ruff CT, Giugliano RP, Braunwald E, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014;64(6):576-584. 117. Zhou S, Sheng XY, Xiang Q, Wang ZN, Zhou Y, Cui YM. Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(6):602-611. 118. Airee A, Guirguis AB, Mohammad RA. Clinical outcomes and pharmacists acceptance of a community hospital s anticoagulation management service utilizing decentralized clinical staff pharmacists. Ann Pharmacother. 2009;43(4):621-628. 119. Arbring K, Uppugunduri S, Lindahl TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res. 2013;13(1):85. 120. Biscup-Horn PJ, Streiff MB, Ulbrich TR, Nesbit TW, Shermock KM. Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother. 2008;42(6):777-782. 121. Chamberlain MA, Sageser NA, Ruiz D. Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam Pract. 2001;14(1):16-21. 122. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641-1647. 123. Duran-Parrondo C, Vazquez-Lago JM, Campos-Lopez AM, Figueiras A. Impact of a pharmacotherapeutic programme on control and safety of long-term anticoagulation treatment: a controlled follow-up study in Spain. Drug Saf. 2011;34(6):489-500. 124. Ernst ME, Brandt KB. Evaluation of 4 years of clinical pharmacist anticoagulation case management in a rural, private physician office. J Am Pharm Assoc. 2003;43(5):630-636. 125. Garton L, Crosby JF. A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability. J Thromb Thrombolysis. 2011;32(4):426-430. 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3287 126. Gill JM, Landis MK. Benefits of a mobile, point-of-care anticoagulation therapy management program. Jt Comm J Qual Improv. 2002;28(11): 625-630. 127. Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23(3):173-181. 128. Holden J, Holden K. Comparative effectiveness of general practitioner versus pharmacist dosing of patients requiring anticoagulation in the community. J Clin Pharm Ther. 2000;25(1):49-54. 129. Holm T, Deutch S, Lassen JF, Jastrup B, Husted SE, Heickendorff L. Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices. Thromb Res. 2002;105(2):103-108. 130. Lee PY, Han SY, Miyahara RK. Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care. Am J Health Syst Pharm. 2013;70(13):1154-1161. 131. Lee YP, Schommer JC. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. Am J Health Syst Pharm. 1996; 53(13):1580-1583. 132. Lee TY, Po HL, Jin YJ, Tsun WJ, Wang SC. A collaborative care model of anticoagulation therapy in patients with stroke. Neurol Asia. 2011;16(2): 111-118. 133. Levine MA, Shao W, Klein D. Monitoring of international normalized ratios: comparison of community nurses with family physicians. Can Fam Physician. 2012;58(8):e465-e471. 134. Locke C, Ravnan SL, Patel R, Uchizono JA. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist- managed anticoagulation service. Pharmacotherapy. 2005;25(5):685-689. 135. Nichol MB, Knight TK, Dow T, et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother. 2008;42(1):62-70. 136. Patel-Naik B, Szeinbach SL, Seoane-Vazquez E, Snider MJ, Hevezi MS. Managing oral anticoagulation therapy by pharmacists in a specialty heart hospital. J Eval Clin Pract. 2010;16(1):192-195. 137. Poon IO, Lal L, Brown EN, Braun UK. The impact of pharmacist-managed oral anticoagulation therapy in older veterans. J Clin Pharm Ther. 2007;32(1): 21-29. 138. Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105-112. 139. Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015;313(14):1443-1450. 140. Stafford L, Peterson GM, Bereznicki LR, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. Ann Pharmacother. 2011;45(3):325-334. 141. Thanimalai S, Shafie AA, Hassali MA, Sinnadurai J. Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital. Int J Clin Pharm. 2013;35(5):736-743. 142. Wallvik J, Sja lander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007;25(2):123-128. 143. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995;15(6):732-739. 144. Witt DM, Humphries TL. A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care. J Thromb Thrombolysis. 2003;15(2):113-118. 145. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127(5):1515-1522. 146. Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O Shea P. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12(1):88. 147. Lalonde L, Martineau J, Blais N, et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J. 2008;156(1):148-154. 148. Chua WB, Cheen HH, Kong MC, Chen LL, Wee HL. Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore. Int J Clin Pharm. 2016;38(5):1230-1240. 149. Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med. 2000;15(1):31-37. 150. Aziz F, Corder M, Wolffe J, Comerota AJ. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg. 2011;54(5):1404-1407. 151. Chang JY, Wang CC, Kang HC, Shen LJ, Huang CF. Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a medical center in Taiwan. Int J Qual Health Care. 2017;29(6):817-825. 152. Wong PY, Schulman S, Woodworth S, Holbrook A. Supplemental patient education for patients taking oral anticoagulants: systematic review and meta- analysis. J Thromb Haemost. 2013;11(3):491-502. 153. Clark CM, Bayley EW. Evaluation of the use of programmed instruction for patients maintained on Warfarin therapy. Am J Public Health. 1972;62(8): 1135-1139. 154. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013;8(9):e74037. 155. Laporte S, Quenet S, Buchmu ller-Cordier A, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost. 2003;89(3):458-467. 156. Marini BL, Funk K, Kraft MD, et al. The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: a pilot study. Patient Educ Couns. 2014;96(2):264-267. 157. Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns. 2007;69(1-3):145-157. 158. Pernod G, Labare re J, Yver J, et al. EDUC AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med. 2008;23(9):1441-1446. 159. Vormfelde SV, Abu Abed M, Hua TD, Schneider S, Friede T, Chenot JF. Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. Dtsch Arztebl Int. 2014;111(37):607-614. 160. Vrijens B, De Geest S, Hughes DA, et al; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705. 161. DiMatteo MR. Variations in patients adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3): 200-209. 162. Kimmel SE, Troxel AB, French B, et al. A randomized trial of lottery-based incentives and reminders to improve warfarin adherence: the Warfarin Incentives (WIN2) Trial. Pharmacoepidemiol Drug Saf. 2016;25(11):1219-1227. 163. Kimmel SE, Troxel AB, Loewenstein G, et al. Randomized trial of lottery-based incentives to improve warfarin adherence. Am Heart J. 2012;164(2): 268-274. 164. Machtinger EL, Wang F, Chen LL, Rodriguez M, Wu S, Schillinger D. A visual medication schedule to improve anticoagulation control: a randomized, controlled trial. Jt Comm J Qual Patient Saf. 2007;33(10):625-635. 165. Neiman AB, Ruppar T, Ho M, et al. CDC grand rounds: improving medication adherence for chronic disease management - innovations and opportunities. MMWR Morb Mortal Wkly Rep. 2017;66(45):1248-1251. 166. Andrews JC, Schu nemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation s direction and strength. J Clin Epidemiol. 2013;66(7):726-735. 167. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630-1639. 168. Clark NP, Witt DM, Davies LE, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015;175(7):1163-1168. 169. Birnie DH, Healey JS, Wells GA, et al; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084-2093. 170. Beyer-Westendorf J, Gelbricht V, Fo rster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888-1896. 171. Douketis JD, Wang G, Chan N, et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016;14(1):89-97. 172. Godier A, Martin AC, Leblanc I, et al. Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res. 2015;136(4):763-768. 173. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10(4):483-489. 174. Schulman S, Carrier M, Lee AY, et al; Periop Dabigatran Study Group. Perioperative management of dabigatran: a prospective cohort study. Circulation. 2015;132(3):167-173. 175. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166(4):391-397. 176. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet. 2000; 356(9241):1551-1553. 177. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol. 2005;46(4):732-733. 178. Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul Fibrinolysis. 2001;12(1):9-16. 179. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293-300. 180. Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost. 2002;88(1):48-51. 181. Bussey HI, Bussey M, Bussey-Smith KL, Frei CR. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study. Pharmacotherapy. 2013;33(11):1136-1146. 182. Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116(5):879-890. 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3289 183. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45(5):1113-1118, discussion 1118-1119. 184. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243. 185. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566-573. 186. Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L. 3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis. 2016;42(1):19-26. 187. Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. Clin Ther. 2010;32(14):2478-2493. 188. Majeed A, A gren A, Holmstro m M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017;130(15):1706-1712. 189. Yoshimura S, Sato S, Todo K, et al; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) Study Investigators. Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: the SAMURAI-NVAF study. J Neurol Sci. 2017;375:150-157. 190. Gerner ST, Kuramatsu JB, Sembill JA, et al; RETRACE II (German-Wide Multicenter Analysis of Oral Anticoagulation-Associated Intracerebral Hemorrhage II) Investigators. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83(1):186-196. 191. Grandhi R, Newman WC, Zhang X, et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg. 2015;84(6):1956-1961. 192. Schulman S, Gross PL, Ritchie B, et al; Study Investigators. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost. 2018;118(5):842-851. 193. Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106(3):429-438. 194. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-1141. 195. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-520. 196. Held V, Eisele P, Eschenfelder CC, Szabo K. Idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran. Case Rep Neurol. 2016;8(3):224-228. 197. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431-441. 198. De Luca G, Parodi G, Antoniucci D. Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta- analysis. J Thromb Thrombolysis. 2010;30(4):452-458. 199. Newhall KA, Saunders EC, Larson RJ, Stone DH, Goodney PP. Use of protamine for anticoagulation during carotid endarterectomy: a meta-analysis. JAMA Surg. 2016;151(3):247-255. 200. Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg. 1997;13(4):394-397. 201. Pan M, Sua rez de Lezo J, Medina A, et al. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation. Am J Cardiol. 1997;80(10):1336-1338. 202. Kaneda H, Suzuki J, Hosokawa G, Tanaka S, Hiroe Y, Saito S. Impact of heparin neutralization by protamine on restenosis after coronary stent implantation. Int J Cardiol. 2005;105(1):111-112. 203. Mauney MC, Buchanan SA, Lawrence WA, et al. Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg. 1995;22(3):264-269, discussion 269-270. 204. Levison JA, Faust GR, Halpern VJ, et al. Relationship of protamine dosing with postoperative complications of carotid endarterectomy. Ann Vasc Surg. 1999;13(1):67-72. 205. Dellagrammaticas D, Lewis SC, Gough MJ; GALA Trial Collaborators. Is heparin reversal with protamine after carotid endarterectomy dangerous? Eur J Vasc Endovasc Surg. 2008;36(1):41-44. 206. Stone DH, Nolan BW, Schanzer A, et al. Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke. J Vasc Surg. 2010;51(3):559-564. 207. Mazzalai F, Piatto G, Toniato A, Lorenzetti R, Baracchini C, Ballotta E. Using protamine can significantly reduce the incidence of bleeding complications after carotid endarterectomy without increasing the risk of ischemic cerebral events. World J Surg. 2014;38(5):1227-1232. 208. Morales Gisbert SM, Sala Almonacil VA, Zaragoza Garc a JM, Genove s Gasco B, Go mez Palone s FJ, Ortiz Monzo n E. Predictors of cervical bleeding after carotid endarterectomy. Ann Vasc Surg. 2014;28(2):366-374. 209. Treiman RL, Cossman DV, Foran RF, Levin PM, Cohen JL, Wagner WH. The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma. J Vasc Surg. 1990;12(4):440-445, discussion 445-446. 210. Salles LR, Puech-Le o P, Netto BM, et al. Risk factors of stroke in carotid endarterectomy [in Portuguese]. Rev Hosp Clin Fac Med Sao Paulo. 1997; 52(6):291-294. 211. Liu Q, Chen YX, Ni L, Chen Y, Liu CW. Clinical observation of neutralizing heparin with protamine in carotid endarterectomy [in Chinese]. Zhonghua Yi Xue Za Zhi. 2013;93(33):2650-2653. 212. Thuesen L, Andersen HR, B tker HE, Dalby Kristensen S, Krusell LR, Lassen JF. In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention. EuroIntervention. 2005;1(1):66-69. 213. Rossi ML, Zavalloni D, Scatturin M, Gasparini GL, Lisignoli V, Presbitero P. Immediate removal of femoral-sheath following protamine administration in patients undergoing intracoronary paclitaxel-eluting-stent implantation. Expert Opin Pharmacother. 2007;8(13):2017-2024. 214. McDonald JS, Kallmes DF, Lanzino G, Cloft HJ. Protamine does not increase risk of stroke in patients with elective carotid stenting. Stroke. 2013;44(7): 2028-2030. 215. Welling RE, Ramadas HS, Gansmuller KJ. Cervical wound hematoma after carotid endarterectomy. Ann Vasc Surg. 1989;3(3):229-231. 216. Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost. 2015;114(4):819-825. 217. Chen WC, Chen YH, Hsu PI, et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. BioMed Res Int. 2014;2014:463767. 218. Claassen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol. 2008;65(10):1313-1318. 219. Gathier CS, Algra A, Rinkel GJ, van der Worp HB. Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy. Cerebrovasc Dis. 2013;36(1):33-37. 220. Guha D, Coyne S, Macdonald RL. Timing of the resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: a retrospective cohort study. J Neurosurg. 2016;124(3):750-759. 221. Hernandez I, Zhang Y, Brooks MM, Chin PK, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017;48(1):159-166. 222. Majeed A, Wallvik N, Eriksson J, et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost. 2017;117(3):491-499. 223. Mirzayan MJ, Calvelli K, Capelle HH, Weigand J, Krauss JK. Subdural hematoma and oral anticoagulation: a therapeutic dilemma from the neurosurgical point of view. J Neurol Surg A Cent Eur Neurosurg. 2016;77(1):31-35. 224. Nielsen PB, Larsen TB, Skj th F, Lip GY. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med. 2017;177(4):563-570. 225. Osaki M, Koga M, Maeda K, et al; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. A multicenter, prospective, observational study of warfarin-associated intracerebral hemorrhage: the SAMURAI-WAICH study. J Neurol Sci. 2015;359(1-2):72-77. 226. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation [published correction appears in Am J Cardiol. 2015;116(1):166]. Am J Cardiol. 2014;113(4):662-668. 227. Sengupta N, Feuerstein JD, Patwardhan VR, et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study [published correction appears in Am J Gastroenterol. 2015; 110(3):480]. Am J Gastroenterol. 2015;110(2):328-335. 228. Teo KC, Mahboobani NR, Lee R, et al. Warfarin associated intracerebral hemorrhage in Hong Kong Chinese. Neurol Res. 2014;36(2):143-149. 229. Witt DM, Clark NP, Martinez K, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thromb Res. 2015;136(5):1040-1044. 230. Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012;172(19):1484-1491. 231. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-836. 232. Majeed A, Kim YK, Roberts RS, Holmstro m M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke. 2010;41(12): 2860-2866. 233. Yung D, Kapral MK, Asllani E, Fang J, Lee DS; Investigators of the Registry of the Canadian Stroke Network. Reinitiation of anticoagulation after warfarin- associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol. 2012;28(1):33-39. 234. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e152S-e184S. 235. Schu nemann HJ, Wiercioch W, Brozek J, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-110. 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3291